Tokyo, Japan, – Sept. 20, 2006 – REGiMMUNE Corporation announced today the appointment of Dr. Yasuyuki ISHII, Team Leader of the Laboratory for Vaccine Design at the RIKEN Research Center for Allergy and Immunology (RCAI),

“We are delighted to have a world-renowned researcher with expertise in immunology and molecular biology providing us with advice to strengthen REGiMMUNE’s growing platform technology and business focus in the areas of immune regulation and clinical immunology,” commented Mr. Haru MORITA, President and Chief Executive Officer.

Dr. ISHII is the Team Leader of Vaccine Design team at RCAI in Kanagawa, Japan, which is a leading research institute in the areas of allergy and immunology. He is an expert in immune regulation and his pioneering work has led to the fundamental elucidation of regulatory mechanisms in the immune system and to immune regulatory platform technologies.

REGiMMUNE (ja.regimmune.com) is a biotechnology company focused on the immune regulating system for product development using a patented platform technology that can activate the immune regulation system. The technology has been successfully applied to reVax technology, which generated REGiMMUNE’s own pipeline. The company is currently focusing its platform on the development and manufacturing of therapeutic compounds for the treatment of allergies and autoimmune disease.

For Information Contact:
Yuko Amizaki, Director, Corporate Planning
REGiMMUNE.
+81-3-3456-0820
For conact via e-mail, please click here.